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The migrating motility complex (MMC), a cyclical phenomenon, represents rudimentary motility pattern in the
gastrointestinal tract. The MMC is observed mostly in the stomach and gut of man and numerous animal species. It
contains three or four phases, while its phase III is the most characteristic. The mechanisms controlling the pattern are
unclear in part, although the neural control of the MMC seems crucial. The main goal of this article was to discuss the
importance of intrinsic innervation of the gastrointestinal tract in MMC initiation, migration, and cessation to
emphasize that various MMC-controlling mechanisms act through the enteric nervous system. Two main neural
regions, central and peripheral, are able to initiate the MMC. However, central regulation of the MMC may require
cooperation with the enteric nervous system. When central mechanisms are not active, the MMC can be initiated
peripherally in any region of the small bowel. The enteric nervous system affects the MMC in response to the luminal
stimuli which can contribute to the initiation and cessation of the cycle, and it may evoke irregular phasic contractions
within the pattern. The hormonal regulators released from the endocrine cells may exert a modulatory effect upon the
MMC mostly through the enteric nervous system. Their central action could also be considered. It can be concluded
that the enteric nervous system is involved in the great majority of the MMC-controlling mechanisms.
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The so-called “motor complex” is the composed cyclic phenomenon traveling along the
gastrointestinal tract and propelling the contents. Consequently, it is named the “migrating
complex” (43, 313). The name “migrating electric complex” (262) or “migrating myoelectric
complex” (42) was proposed when it was recorded utilizing the myoelectrical technique.
When the mechanical recording method was applied, the name “migrating motor complex”
was used (63, 141). A more uniform name, the “migrating motor complex” (MMC), as
proposed by Weisbrodt (302) and used by others (96), applied regardless of the recording
system, is also actual. When the MMC was referred to man, dog, or some other species in
which the cycle is disrupted after a meal, the word “interdigestive” was added to the name of
the cycle (35, 58). Although the term “interdigestive migrating complex” could be disputable,
it is currently in use in monogastrics (265, 300). In rats, short MMC cycles, observed in the
fasting state, can be substantially prolonged in the upper small intestine after feeding (29). In
fasted guinea pigs, the duration of the MMC is similar to that in man or dog, but after feeding,
it is prolonged (85). In ruminants, especially in sheep, the MMC also occurs in the postfeeding
period. Therefore, in the ruminant species, in which no interdigestive period is present, the term
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“interdigestive MMC” might be misleading (31). It is noteworthy that in sheep, the MMC
cycles disappear in response to overfeeding. In pigs, as in ruminants, the same name of the
pattern can be used, despite the MMC is more closely related to feeding (218). The MMC
occurs principally in the stomach and small bowel and it is one of the basic motility patterns
important for characterizing the gastrointestinal motility (106, 213). The cycle also arrives in
the colon and it is independent of its presence in the small bowel (152, 224).
Basic Characteristics of the MMC
Once arrived, the MMC can persist in an undisturbed form returning regularly, cycle by
cycle, even for 24 h and longer. However, its organization is not strictly uniform. As it has
been stated by several authors (28, 251, 325), the MMC cycle duration in man, dog, and
sheep ranges within 90–120 min. However, in these species, some authors described more
variable MMC duration periods like 100–150 min (227), 90–180 min (163), 85–110 min
(117, 152), or 60–110 min (302). In man, according to Woodtli and Owyang (318), typical
MMC cycles lasted for 80 ± 27 min and atypical ones for 115 ± 35 min. In rats, duration of
the MMC in the stomach was 16 ± 5 min whereas in the duodenum and jejunum, the values
were 13 ± 6 and 16 ± 6 min, respectively (6, 9). In another report, the duration of the MMC
cycles was 11 ± 6 min in the antrum of the fed rats and 11 ± 8 min in the duodenum (82). In
fasted rats, the MMC cycle frequency can be even higher in the upper than in the lower small
bowel since several complexes recorded in the jejunum never reach the ileum (29). Duration
of the MMC in fasted sheep lasts usually for about 1 h or less (215). In sheep, undergoing the
standard feeding regimen, duration of the MMC cycle was reported to be either 1 h (212) or
70–90 min long (29, 215). When feeding with hay was supplemented with the addition of the
concentrate, these values averaged from 90 to 144 min (29). Thus, the variability in the
duration of the MMC can be substantial.
Within the MMC cycle, four phases are discernible (42). As proposed by Code and
Marlett (42), the MMC phases are numbered consecutively due to the gradually enhanced
gastrointestinal motor activity. Accordingly, during phase I, no or almost no contractions and
spike bursts are present. In the course of phase II, the contractions and spike bursts become
more intense reaching the apogeum during phase III of the cycle. Phase IV is observed in the
most cases and its irregular character resembles phase II of the MMC. Similar to the complete
MMC pattern, duration of its phases is also variable although phase variability is not greater
than that of the cycle. In man, the reported average duration of gastric phases I–IV of the
“typical” MMCs was 28, 42, 2.0, and 7.1 min, respectively, whereas in the “atypical” cycles,
it was 31, 80, 3, and 0.8 min, respectively (318). In the human duodenum, the average
durations of the phases I–III of the MMC were 38, 50, and 5 min, respectively (188). In the
duodeno-jejunum of man, the average durations of phases I–III were 20, 123, and 6 min,
respectively (255). In the human jejunum, the average durations of phases I–III were 28,
59, and 4 min, respectively (13). In the canine proximal stomach, the average durations of
phases I–III were 52, 34, and 24 min, respectively, whereas in the distal stomach, the
values equaled to 60, 30, and 19 min, respectively (89). In a broader canine study, mean
durations of the gastric MMC phases I–IV were 53, 23, 18, and 6 min, respectively, the
durations of duodenal phases were about 38, 46, 8, and 7 min, respectively and in the
jejunum, these phases lasted 48, 46, 5, and 2 min, respectively (231). Another study in dog
showed that the mean durations of duodenal phases I–IV were 69, 20, 9, and 2 min,
respectively (227). In the canine jejunum, the duration periods were equal to 40, 35, and 8
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for phases I–III, respectively (28). In the same study, the durations of the ovine jejunal
phases I–III were 42, 40, and 6 min, respectively. In this study, phase IV was rather absent.
In fasted guinea pigs, the reported durations of phase I in the duodenum, jejunum, and
ileum averaged 10, 12, and 13 min, respectively. The relevant values for phase II were
about 70, 67, and 72 min and for phase III, 3, 4, and 4 min, respectively. In fed animals,
duration of phase I in the duodenum, jejunum, and ileum was about 7, 11, and 9 min,
respectively and the relevant values for phases II and III were 118, 161, and 123 min and 3,
5, and 4 min, respectively (85). No report demonstrating the complete absence of a given
phase in the course of normal MMC cycle in man and animals is available. Regular phase
organization of the MMC, despite individual and species differences, allows to perceive
the importance of its neural control and suggests the presence of distinct controlling
mechanisms for each phase of the cycle.
The propagation velocity of the MMC is most characteristic for a given cycle once it is
determined for phase III. Sometimes, it is also measured for phase II. In man, the reported
duodenal migration velocity of phase III was approximately 11 cm/min (63), 20 cm/min
(129), 12 cm/min (76), or 8 cm/min (7). In the human duodeno-jejunum, the reported values
of the migration velocity of phase III were 9.3 cm/min (63) or about 6 cm/min (141, 255). In
the upper jejunum, migration velocity of phase III was also 6 cm/min (76). In the human
jejunum, similar values were observed, i.e., 6 cm/min (7), 7 cm/min (63), or 5 cm/min (136).
In man, the ileal migration velocity of phase III was much slower and oscillated around 1 cm/
min (136). In dog, propagation velocity of phase III of the MMC in the duodenum was about
5 cm/min (260). In the canine duodeno-jejunum, it averaged about 4 cm/min (29, 262). In the
proximal jejunum of this species, the values were about 4 cm/min (29). Other reported values
regarding propagation velocity of the jejunal phase III were equal to 2–3 cm/min (260) or to
about 6–7 cm/min (235). In the canine ileum, migration velocity of phase III was below 2 cm/
min (262). In the hog’s jejunum, migration velocity of phase III was about 19 cm/min (141).
In sheep, the mean propagation velocity from the duodenum till the ileum was about 19 cm/
min (29), whereas in the proximal jejunum this value was 26 cm/min (141). In the duodeno-
jejunum of rats, propagation velocity of the MMC was 2 cm/min or slightly faster (6). When
the normal MMC cycle is considered, migration of phase III and of the whole cycle occurs
regardless of the site of pattern origin. The migration of phase III in the small bowel as well as
the migration of the whole cycle over the long distance suggests the presence of many
inducing units in the subsequent intestinal segments. The units are well coordinated
functionally and linked probably with the enteric nervous system. The organized migration
along the bowel of each normal MMC cycle, with remarkable regularity, must be steered by
ﬁne control mechanisms involving the enteric network of intramural neurons. The smooth
muscles are regarded merely as the effector organ. The composed arrangement, recurrence,
variability, and well-organized migration of the MMC appear to be compelling elements for
its imprecise, but repeatable organization.
Luminal Conditions and the MMC
The phases II and III of the MMC are propulsive regardless of the animal species and feeding
regimen. When the duodeno-jejunal ﬂow of digesta was compared in dog and sheep, the
postcibal ﬂow of the chyme was greater in the dog, whereas the interprandial ﬂow (10 h after
feeding) or after saline administration was comparatively lower in this species (29). The
transit time in sheep after saline administration was slower than in the dog (28). Furthermore,
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in sheep, the digesta ﬂow is not constant that can further slower its average ﬂow rate through
the bowel (97, 112). In both animal species, it was the slowest in the jejunum during phase I
and much more rapid during phases II and III of the MMC. When the two latter phases were
compared, the transit time was faster during phase II than during phase III of the MMC in
both the dog and sheep. However, in these animals, changes in bolus migration velocity
during the MMC phases were similar (28). It was found in man that the relation of propagated
to stationary contractions during phase III was 1:1 and during phase II it was about 5:1 (3). In
man, migration velocity and related propulsion during phase III were slower than during
phase II since the migration of phase III was not completely antegrade (8, 17). It is possible
that the intensity of digesta ﬂow is one of the factors regulating the arrival of the MMC cycle
in both the stomach and small intestine. It seems unlikely that the mechanisms controlling the
intestinal transit so precisely, are not related to the nervous system. The movement of the
luminal contents, either in the digestive or in the interdigestive periods, activates several
controlling mechanisms due to the contact of chyme with the intestinal mucosa that contains
mostly numerous mechanoreceptors and chemoreceptors. The stimulation of these receptors
regulates the motility and transits either in the fasting state or postprandially.
Cessation of the phase III is practically tantamount to the disruption of whole MMC
pattern. Feeding seems to be the most natural disruptive factor, at least in man (259, 290),
dog (42, 58), and some other monogastrics. Only sufﬁcient amount of food can disrupt the
MMC (304). In the dog, if the size of a meal is too small or duration of fasting is not long,
the intestinal digesta ﬂow does not exceed the rate 20–30 ml/h. Then, the MMC is not
disrupted (217). When the meal is relatively small, it can even provoke phase III arrival when
given during the late phase II, but when offered during phase I it can induce irregular
contractions and the motor response is much weaker (165). The presence of ﬂuid or gas in the
gastrointestinal tract may also inﬂuence the MMC. In man, aspiration of ﬂuid and gas from
the upper gastrointestinal tract decreases the duration of phase II and increases the duration of
phase I of the MMC. Moreover, the instillation of acaloric ﬂuid or gas into the stomach may
prolong the duration of phase II (254). Administration of isotonic saline abolished the MMC
for shorter periods than a complete meal either in all or only in 6 of 10 volunteers (242, 309).
In dogs, intraduodenal placement of isoosmotic saline did not abolish the MMC, but slightly
prolonged its average duration from 111 till 118 min due to prolonged duration of phase II. In
this study, low-caloric meal prolonged the MMC cycle till 174 min, with slight shortening of
phase I and substantial elongation of phase II (54). The duration of phase III was rather not
altered. Therefore, shortening of phase I and elongation of phase II can be treated as the
inhibitory tendency toward the MMC inhibition. These results clearly indicate that in normal
conditions, physical factors in the lumen can affect the MMC.
Oral administration of food abolished the MMC for a longer period than enteral
nutrition (205). Interestingly, when the effect of intragastric feeding was compared with
the effect of intraduodenal feeding upon the recurrence time of phase III, the latter procedure
exerted stronger effect (146). The more nutrients are present in food when the longer
disruption of the MMC occurs. The caloric load can thus strongly affect the interdigestive
pattern, especially in such species like man (188, 243) and dog (54, 58, 233). In ruminants,
relatively low-caloric load of the typical diet, especially of the hay given alone, can retain the
MMC during the digestive period (29, 97, 153). However, in sheep, the MMC can be slightly
prolonged after feeding, but the effect seems to be the short lasting and dependent on the
nutrient content, i.e., on the caloric value of the fodder (29, 98). The ﬁnal effect of the caloric
content of food upon the MMC is related to the type of nutrients present in food. In dogs,
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duration of MMC inhibition by lipids is the longest when compared with peptides or glucose;
whereas in man, the effects of glucose and fat are not much different (233, 242). When Thiry-
Vella loop was perfused with glucose-containing solutions, disruption of the MMC was
limited to the loop indicating the local inﬂuences as it was noticed in the dog (69). In man, the
intraduodenal infusion of medium-chain and long-chain triglycerides exerted different effect
on the MMC in the gut. When medium-chain triglycerides were infused, no MMC disruption
was denoted. Following the infusion of the long-chain triglycerides, the opposite effect was
observed (292). When the effects of very long-chain and long-chain triglycerides were
compared after intraduodenal infusion in healthy volunteers, about 46% and 23%
of the MMC cycles were inhibited, respectively (129). The infusion of arachis oil, mixed
with bile and pancreatic juice, into the duodenum and ileum disrupted the MMC in dogs.
When the arachis oil was infused alone, disruption of the MMC was observed only in the
duodenum (70). Intraileal infusion of the oleic acid emulsion in dogs also prolonged the
length of the MMC cycle, exerting general inhibitory effect upon the small intestinal
motility (65). Therefore, the effectiveness of lipids in the inhibition of the MMC is mostly
related to the type of lipid and its digestion in the gut. The digestion products can trigger the
MMC-inhibitory mechanisms and affect the cycle. The duodenal distension inhibited phase
III-like spike bursts and induced the antro-pyloro-duodenal motor activity in the fasted
state (67, 80). Physiological changes in the intraluminal pH (acidiﬁcation and alkalization)
exerted stimulatory effect upon the MMC (121, 155, 162, 318). Intrinsic innervation is
involved in the MMC control both during the fasted and the fed state and cooperates with
hormones (16, 106). The afferent neural ﬁbers originating from the mucosa transmit the
signals from the lumen to the intramural ganglia (41, 100). The effectiveness of relatively
weak intraluminal signals in their inﬂuence upon the MMC implies that the nervous system
plays the major mediatory role in this regulation. Clear inhibitory effects upon the MMC,
evoked by intraileal lipid infusions, might be strengthened and/or mediated also by the local
hormonal inﬂuences. It is thus likely that the luminal factors may contribute to both the
initiation and cessation of the MMC as well as to the MMC phase duration and may also
modulate the irregular phasic contractions within the pattern by means of the neurohormonal
mechanisms.
Peripheral Peptidergic Control of the MMC
Several regulatory substances can induce the phase III of the MMC and new regulators,
affecting the MMC, are discovered almost every decade (301). They comprise the gastroin-
testinal hormones and some other chemical factors, mostly neuromodulators (60, 213, 303,
305). They represent endogenous peptide and non-peptide regulators and various xenobio-
tics. These regulators act rather peripherally and their action may possibly involve extrinsic
mechanisms when they can cross the blood–brain barrier. However, the peptide regulators
can pass this barrier usually in low quantities (128). They can bind to the receptors, located on
extrinsic afferents within the gastrointestinal tract, which provokes the efferent extrinsic
response. Furthermore, after postprandial inhibition, the MMC appears to return spontane-
ously, i.e., when activity of the inhibitory mechanisms declines without the evident
contribution of additional inﬂuencing factors (29). Hormonal involvement is suspected to
be important in the inhibition of the MMC by nutrients (15, 91). These regulators can act in
part as hormones, and in part as neuromodulators. It is uncertain whether the role of
postprandially released hormones is the cause or consequence of the cessation of the MMC
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cycles. It is also unclear that the exact role of the enteric nervous system is in the hormonal
actions regarding the MMC. There are also several reasons to suggest the occurrence of
exclusive neural inﬂuences in the control of the MMC (40, 186). The autonomic nervous
system is responsible for these effects and it is equipped with some speciﬁc mechanisms,
engaging the neuropeptides as well.
Motilin
Motilin was found to induce the premature phase III of the MMC during fasting in such
species like man and dog (122, 290, 316). During the interdigestive period, plasma motilin
concentration ﬂuctuates in concert with phase III in the stomach of the species (122, 291).
Motilin antibodies disrupted naturally occurring MMC in the proximal small bowel but not in
the jejunum and ileum (148, 194). Motilin antagonists exerted a similar effect (176). Acid,
alkali, and fat can induce motilin release, increasing its level in the blood, particularly in dogs
(20, 45, 149). Glucose and amino acids can decrease plasma motilin levels (37). Thus, the
data suggest that motilin itself can probably initiate phase III of the MMC, acting as the gut
hormone released from the duodenal mucosa, although it remains obscure whether or not
the endocrine action is accompanied by the involvement of the nervous system. It is in the
stomach where motilin appears to be the most important for evoking the MMC. It may initiate
phase III there, probably in some cooperation with other chemical regulators (131, 265). It
was found that the induction of phase III of the MMC in the human stomach, unlike in the
small bowel, was motilin-dependent (127). Motilin receptors, present in the pyloric antrum,
are mostly located on nerves (170, 263, 319). Therefore, the neuronal action of motilin-
induced phase III in the stomach is very probable. Other data indicate that small intestinal
contractions can induce motilin release thus increasing plasma motilin concentration to the
level sufﬁcient to induce phase III of the MMC (223). This view also conﬁrms the existence
of an endocrine pathway for motilin action, although it is not known whether the mechanisms
are sufﬁcient to trigger the MMC in normal conditions. The motilin-producing cells were
found mostly in the duodeno-jejunum and they produce the major portion of endogenous
motilin (197). Motilin may thus be able to induce phase III of the MMC in an endocrine
pathway, acting directly on the smooth muscles since the motilin receptors are present there
(267). However, the substantial portion of motilin receptors occurs also in nerves (107, 267).
It is possible that the greater motilin receptor density, as present in the intestinal smooth muscle,
unlike in nerves, may be required to induce the MMC. It is also highly probable that the
stimulation of neuronal motilin receptors is more efﬁcient in the induction of the MMC than the
direct action on the smooth muscle. The endocrine pathway can thus be important rather for
stimulation of individual phasic contractions. The neurocrine action of motilin is more probable
for the induction of phase III of the MMC because of its composed organization and evoking
mechanisms. Other neural mechanisms, including those linked with biological clocks, might be
engaged as well. It is known that in the postprandial state motilin does not evoke phase III in
normal conditions, because its level in the blood is suppressed and its ﬂuctuations in the blood
are abolished. When exogenous motilin is supplied during the digestive state, phase III cannot
be induced (125, 317). Motilin proves to be effective in the modulation of gastric emptying of
liquids and solids in man and dog (38, 53). Since phase III is not evoked postprandially in these
species, it appears that motilin can trigger the propulsive contractions despite its lowered level
in plasma. Endogenous motilin, released in response to morphine administration in the fed
state, is suspected to induce phase III (225). The rabbit motilin antiserum did not decrease
plasma motilin level completely (18). The duodenectomy also decreased plasma motilin level
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only in part (271). This may further conﬁrm that there is still another pathway for the motilin
action and the source of motilin release, since in the postprandial period, nutrients and
hormones, such as secretin or pancreatic polypeptide (PP), can hamper motilin-evoked effect
(37, 126, 172). There are several reasons to assume that motilin release from endocrine cells, in
response to various regulatory factors, can be ampliﬁed by intestinal contractions. It may help to
achieve the sufﬁcient motilin level for the induction of phase III of the MMC or for potentiation
of motility only (223). The mechanism can be treated as supplementary for endocrine release
and action of motilin.
Apart from the endocrine mechanism, there are three other possible mechanisms or
groups of mechanisms of motilin release and action.
[A] First possible neural mechanism of motilin release and action is linked to the vagus
nerve cooperating with the enteric nervous system. Motilin is present in the vagus (120). The
MMC-related plasma motilin ﬂuctuation and motilin release by vagal stimulation were
abolished by hexamethonium (78, 150). The electrical vagal stimulation increased motilin
release (147). Thus, the vagal pathways involved in motilin release comprise primarily the
nicotinic receptors (78). On the contrary, vagal stimulation by insulin-dependent hypergly-
cemia or sham feeding depressed motilin release, at least in dogs (151). Vagal cooling slightly
increases motilin levels during fasting. Following vagal blockade, the motilin level and the
MMC may remain unchanged (103). The effects of vagotomy are inconsistent, thus, they
might be different from those of vagal cooling (103, 151, 323). In man, vagotomy
surprisingly increased motilin levels (83). It has also been demonstrated that in fed animals
motilin induced phase III of the MMC after vagotomy (173). However, after vagotomy
phase III contractions were less potent than before vagotomy (268). These results are still
difﬁcult to interpret and it is too speculative to propose to what extent the vagal-dependent
mechanisms can operate. The vagus nerve might be involved in the initiation of the MMC and
the contribution of motilin to this mechanism is very probable.
[B] The second mechanism responsible for motilin release and action is conﬁned to the
cholinergic mechanisms, located in the enteric nervous system. Motilin as well as its
receptors are present in the intramural neurons (78, 267). The intrinsic excitatory pathways
for motilin release involve neural endings with muscarinic receptors present on both motilin
cells and the smooth muscles. The electrical stimulation of intrinsic nerves releases motilin
(78). Motilin can exert excitatory effect upon the myenteric neurons in the small bowel (130).
It has been demonstrated that atropine, unlike hexamethonium, blocked motilin release
evoked by the carbachol since the muscarinic receptors are present on the motilin cells (321).
Several weeks following vagotomy, motilin ﬂuctuated in accordance with the MMC, exactly
as before the surgery, suggesting that the intramural cholinergic neurons might not be
important for motilin secretion, at least in the dog (151). In the duodenum, the phase III of the
MMC is not always accompanied by motilin peaks, whereas in the jejuno-ileum there is
virtually no correlation (223).
[C] A third group of mechanisms is linked to the neuroendocrine pathway of motilin-
dependent control of the MMC. The stimulatory non-adrenergic non-cholinergic (NANC)
neurons may thus be engaged, since several endogenous regulators can induce phase III (213,
223). The regulators can initiate phase III of the MMC directly or in cooperation with the
motilin-containing neurons. If the group of mechanisms is sufﬁcient to evoke the MMC, the
plasma level of motilin can remain unrelated to the induction of the pattern. When exogenous
motilin evokes the release of endogenous peptide acting on motilin receptors located on
intrinsic neurons, both the preganglionic and postganglionic pathways may contribute to this
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action. It indicates the possible involvement of the enteric nervous system in the endocrine
mechanism of motilin release and action (174). Therefore, it can represent a mixed
endocrine–neuroendocrine mechanism and the question is raised whether or not a pure
endocrine mechanism of motilin release and action exists and if it is sufﬁcient to evoke the
MMC. The combined endocrine–neuroendocrine mechanism of motilin release seems to be
more efﬁcient in the generation of phase III, since more motilin can be released than in the
situation when the enteric nervous system is not involved (124).
The existence of the composed mechanism, governing the induction of phase III by
motilin seems very probable because of possible involvement of the relaxation oscillators
coupled within the interstitial cells of Cajal and/or within the various types of intrinsic
neurons. The neurons are responsible not only for the initiation of phase III but also for the
coordination and migration of the whole MMC cycle (223).
Finally, it can be asserted that the role of motilin as the neuromodulator in the initiation
of phase III of the MMC seems more probable and important than its rather supportive role as
the gut hormone. Motilin action is apparently mediated by central and peripheral neural
mechanisms regulating the MMC and both these groups of mechanisms seem to be important
(40, 118, 222).
Serotonin
Serotonin (5-hydroxytryptamine, 5-HT) is the omnipresent regulator found in the brain,
although about 95% of the substance occurs within the gastrointestinal tract (137). The
principal gastrointestinal 5-HT depot is located in the enterochromafﬁn cells (87). 5-HT is
thus a tissue hormone as well as a neurotransmitter acting within the enteric nervous system,
presumably as a member of the NANC system. In various animal species, it exerts
stimulatory effects on gastrointestinal motility, including the MMC initiation (105, 192).
Selective 5-HT reuptake inhibitors reduced the MMC cycling and increased the migration
velocity of its phase III in man (93). In rats, the enteric serotonergic neuron destruction
decreased the MMC cycle (193). The modulatory action of 5-HT upon the MMC is executed
mostly through two 5-HT-receptor subtypes, 5-HT3 and 5-HT4 (19, 116, 273). The 5-HT3-
receptor subtype, called the extrinsic receptor, mediates the motility-inducing serotonergic
transmission from the gastrointestinal tract to the brain, activating the enteric afferent neurons
(87). The extrinsic 5-HT3 receptor, located on vagal afferents, can mediate the initiation of
phase III of the MMC from the stomach, both of man and dog, or from the small bowel of the
rat, through acetylcholine release and, possibly, through motilin release (123, 161, 312).
5-HT1- and 5-HT4-receptor subtypes, called intrinsic receptors, enhance the release of the
transmitter within the enteric nervous system from the terminals of prokinetic circuits. The
receptors are located in the myenteric plexus (272, 273). Studies with the speciﬁc antagonists
in dogs conﬁrmed that 5-HT3 receptors are involved in the generation of phase III in the
stomach, whereas 5-HT4 receptors are involved in the generation of phase III of the MMC in
both the stomach and small bowel (180). In the rat’s small intestine, the 5-HT4-receptor
antagonist inhibited the MMC cycles. The application of 5-HT3-receptor antagonist pro-
longed the MMC cycle that can represent only the stage leading to the MMC inhibition (11).
The 5-HT1 receptor is also involved in the control of the MMC. In man, a 5-HT1-receptor
agonist prolonged phase II, while phase I and phase III of the MMC were not affected (33).
Since 5-HT can be released into the small intestinal lumen, where it can mediate motilin
action, the intravenous 5-HT administration can induce phase III of the MMC in the dog (134,
269). 5-HT released from the enterochromafﬁn cells, at least in response to the mucosal
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stimuli, acts as the sensor and can activate 5-HT receptors in the gut. It may rather initiate
local motility changes than affect the whole MMC cycle thus inducing minor alterations in
the upper gastrointestinal tract (105, 277). Serotonin, which acts within the myenteric plexus,
may directly regulate the gastrointestinal motility including the MMC (48, 81, 207). It can be
synthesized either in the neurons or might be uptaken from the blood.
Taking together, it seems likely that in the interdigestive state, 5-HT can affect the
initiation of phase III of the MMC from the stomach in the pathway involving the extrinsic
and intrinsic innervations. In the small bowel, it seems to operate mainly within the enteric
nervous system. In the action of 5-HT upon the MMC, both 5-HT3 and 5-HT4 receptors are
involved, but when the drug activating both 5-HT-receptor subtypes is applied, phase III is
not initiated (19). 5-HT can evoke propulsive contractions and it also participates in other
motility events. Its action combined with motilin can be more effective. It appears that the
5-HT regulates the MMC principally as a neuromodulator. The prokinetic drugs, especially
cisapride, acting mostly through 5-HT3 (as an agonist) and 5-HT4 (as a weak antagonist)
receptors upon the gastrointestinal motility, have been applied as therapeutic agents in the
treatment of gastrointestinal disorders (50, 200, 266, 286) though side effects limit their use.
Ghrelin
Ghrelin is a newer hormone with 36% of the structural homology to motilin and in man, its
receptor resemblance equals ~50% of overall identity with the motilin receptor (36).
However, these hormones have poor crossing afﬁnity to their receptors (i.e., the afﬁnity
of ghrelin to motilin receptors and afﬁnity of motilin to ghrelin receptors); thus, the action of
each of them is mediated by their own speciﬁc receptor. Both hormonal peptides trigger the
MMC, at least in the stomach, and stimulate the gastrointestinal motility. Hence, ghrelin was
termed the “motilin-related peptide” (284). Ghrelin occurs mainly in the endocrine cells of the
stomach (139). It is also present in the duodenal and jejunal mucosa where it can be
synthesized and stored with motilin in the same cell (310). Plasma ghrelin level does not
ﬂuctuate as clearly as motilin in accordance with the MMC, at least in man, but its level
declines after a meal (240). Ghrelin and its receptors are present in the neurons within the
myenteric plexus (319). Exogenous ghrelin can induce phase III-like activity in man, but it
seems likely that in the natural conditions ghrelin level may be insufﬁcient to induce phase III
(34, 264). In fasted rats, ghrelin intensiﬁed the spontaneous phase III-like contractions or
shortened the duodenal cycle length as well as the duration of phase III (9, 300). This action
was mediated by muscarinic, 5-HT, and nitric oxide receptors. Since ghrelin is present in
various gastrointestinal regions, the question arises whether ghrelin contributes to the
regulation of the MMC pattern mostly in the endocrine pathway or as a neuromodulator.
It is also interesting to what extent its cooperation with motilin is inevitable. It has already
been recognized that ghrelin acts not only peripherally, through its receptors located on
myenteric neurons, but the predominant pathway of its action is also transmitting the
information from the gastrointestinal tract through the vagus nerve to the brain (10, 189,
190). It was found in rats that ghrelin induces fasting motor activity by activating the
neuropeptide Y neurons in the brain possibly through the ghrelin receptors located on vagal
afferent neurons. Its central effect was abolished by vagotomy (82). Furthermore, ghrelin
induced phase II of the MMC in Suncus murinus and this response was conducted by vagus
nerve (173). During in vitro studies, large doses of ghrelin, given alone, did not stimulate
contractions in the gastric preparations of Suncus murinus, but when pretreatment with the
low dose of motilin was conducted, ghrelin induced contractions efﬁciently (176).
Peripheral peptidergic and serotonergic control of the MMC 105
Physiology International (Acta Physiologica Hungarica) 104, 2017
It has been shown to date that the control of the MMC by ghrelin can be exerted in both
the extrinsic and intrinsic pathways and ghrelin acts predominantly as a neuromodulator.
Cooperation with motilin could be essential, at least in the stimulation of the gastrointestinal
contractions, but the effects might be species-dependent.
Figure 1 shows possible MMC-controlling mechanisms involving motilin as the
principal neuromodulator with or without cooperation with 5-HT and ghrelin.
Somatostatin
Somatostatin was found in both the brain and periphery. In the gastrointestinal tract it is
synthesized and stored by endocrine D cells that are dispersed mostly in the gastric and
duodenal mucosa and also in the remaining gut segments, whereas in the enteric nervous
system, it is located in the interneurons of submucosal and myenteric plexuses throughout the
Fig. 1. The postulated controlling mechanisms of the migrating motor complex engaging the motilin as a
neuromodulator, with or without cooperation with serotonin (5-HT) and ghrelin. I. Central control of the MMC.
Motilin is released within the afferent vagal ﬁbers and evokes central response transmitted through efferent vagal
ﬁbers. It affects 5-HT release within the enteric neurons, inducing the stimulatory motor response on the smooth
muscle that is ﬁnally mediated by cholinergic muscarinic receptors located on the enteric efferents and/or on the
smooth muscles. II. Peripheral action of motilin released from the enteric neurons or reaching them from the blood.
Final stimulatory motor response on the smooth muscle is mediated by cholinergic muscarinic receptors. This
mechanism can be entirely neurocrine or mixed (endocrine–neuroendocrine). III. Peripheral neural stimulatory or
inhibitory response of the smooth muscle evoked by 5-HT whose release is modulated by motilin operating within
the interneurons of the enteric nervous system. 5-HT can be released from the enteric neurons or can reach the
enteric neurons from the blood. The mechanism can be entirely neurocrine or mixed (endocrine–neuroendocrine).
IV. Peripheral neuronal stimulatory response of the smooth muscle induced by 5-HT and ampliﬁed by motilin
acting within the enteric nervous system. V. Synergistic peripheral neural stimulation of the motor response of the
smooth muscle by motilin and ghrelin acting within the enteric neural network. The ﬁnal response is mediated by
cholinergic muscarinic receptors. Mo: motilin; M: muscarinic receptors; Se: 5-HT; Gh: ghrelin;
: enteric ganglion; : smooth muscle
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digestive tube, particularly in the small intestine (49, 132, 196). In the human gut, only about
10% of somatostatin is located within the muscles and about 90% in the mucosa (191).
However, in the small bowel, somatostatin is mainly located in the neurons within the
submucosal and muscle layers (294). Independently of the intrinsic neurons, somatostatin
was found in the noradrenergic neurons of the sympathetic ganglia. Their ﬁbers project
mainly to the submucosal ganglia of the small bowel and to the regions of vagal nerve ending
in the gut (115, 287). Various types of somatostatin receptors are distributed within the gut
including the enteric nervous system (175). In the gastric antrum and small intestine, but not
in the gastric corpus, D cells (the open secretory cells) project to the lumen that enables a
paracrine action of somatostatin (143). Acids and a variety of neurohumoral factors can
stimulate D cells, whereas acetylcholine inhibits somatostatin release in the D cell-related
pathway (61). Since tetrodotoxin and atropine can inhibit somatostatin release, it can be
presumed that the actions of some luminal stimuli in the gut may be mediated by nerve
endings located on epithelial surface and transmitted to D cells by intrinsic neurons (99, 220).
Plasma somatostatin ﬂuctuates in accordance with the MMC (285). The effect of somatostatin
upon the gastrointestinal motility is complex and mostly inhibitory (320). In the fasting state,
its effect upon the MMC, appears to exhibit a dose-dependent character. Somatostatin,
applied in smaller doses, shortens the MMC cycles, whereas its higher doses exert inhibitory
effects (27, 185, 195, 282). The hormone may locally induce phase III-like activity (114).
When the MMC is induced by somatostatin, its phase II is greatly reduced and phase III is
ectopic. In these MMC cycles, phase I predominates. Somatostatin can cooperate with
motilin in the induction of the MMC in the gut. The occurrence of MMC is not always
associated with the motilin peaks since motilin release can be blocked by somatostatin (75).
Somatostatin can also contribute to the induction of phase III of the MMC in the postprandial
period or after pentagastrin-stimulated fed state (239, 260, 282). Therefore, the hormone can
modulate the MMC, either in the interdigestive or digestive state, and peripheral mechanisms
mediating its action seem to involve the enteric nervous system (117, 298). Centrally evoked
factors may be important in the release and action of somatostatin. It appears that the central
nervous system also contributes to the control of the MMC by the hormone or to the
modulation of the character of interdigestive and postprandial intestinal motility (21, 56, 95).
Somatostatin appears to control the gastrointestinal motility, including the MMC,
mainly in the peripheral neuroendocrine pathways and the enteric nervous system plays a
marked mediatory role in the hormone action. However, contribution of endocrine and
paracrine pathways in the regulation of the MMC by somatostatin remains unclear.
Enkephalins
Natural opioid peptides are known to be active in many regions of the brain and their central
action can also comprise the gastrointestinal motility (169). Among known endogenous
ligands of the opioid receptors, enkephalins can play a role in the control of the MMC. The
role of the opioid mechanism was conﬁrmed with the use of the natural opioid peptides and
xenobiotics exerting their effect through the opioid receptors (228, 229). The opioid receptors
are abundant in the gastrointestinal enteric nervous system, i.e., in the interneurons, although
they are also present in the gastrointestinal smooth muscles (178, 236). While the μ-, κ-, and
δ-opioid receptors contribute to the control of gastrointestinal motility, the μ-type receptor is
involved in principio in the control of the MMC (23, 94). Met-enkephalin is the major
regulator of the MMC, whereas Leu-enkephalin is much less active in this area. Since Met-
enkephalin may exert a presynaptic inhibitory effect on acetylcholine release from the
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myenteric plexus, it seems likely that its interaction with the cholinergic system represents
basic mechanisms affecting the gastrointestinal motility by endogenous opioids (296). Opioid
peptides exerted inhibitory effect on gastric emptying and intestinal transit, and their action
on the smooth muscle contractility was either inhibitory or stimulatory. All the effects were
dose- and species-dependent (23, 169). The application of enkephalin analogues revealed the
substantial contribution of the opioids to the control of the MMC pattern. Met-enkephalin
analogue, Dalamide, when administered centrally at a small dose and intravenously at a
higher dose, disrupted canine fasting antral and jejunal motor activity for the relatively long
time (23, 26). In the fed state, another analogue, like morphine, restored the MMC pattern. It
appeared to act centrally, even when administered intravenously, since it probably crossed the
blood–brain barrier. The described effects of Dalamide, at least on the canine stomach, were
mediated by the μ-type opioid receptor (23, 26). Similar experiments were performed in rats
(206). In fed animals, Dalamide given intracerebroventricularly shortened the postprandial
inhibition of the MMC. When Dalamide was administered intraperitoneally, its effect was the
opposite. Therefore, in rats a dual route-dependent effect was observed (206). The central
action upon the MMC was conﬁrmed with the intracerebroventricular administration of
thiorphan, the enkephalinase inhibitor, which disrupted the MMC pattern in dogs for several
hours. Thiorphan does not cross the blood–brain barrier and its intravenous administration
did not affect the MMC. Leu-enkephalin analogue (DADLE, dominantly δ opioid receptor
agonist) failed to modify the gastrointestinal MMC in both the fasted and fed states.
The scant data suggest that Met-enkephalin affects the MMC through central mechan-
isms which points to its role as a neuromodulator. Therefore, the contribution of the enteric
nervous system to the opioid control of the MMC cannot be excluded. It is also noteworthy
that loperamide and diphenoxylate, the exogenous, mainly peripherally acting opioids, are
commonly used in the treatment of diarrhea in, for example, numerous settings of the
inﬂammatory bowel disease (104). Loperamide, the μ-receptor agonist, attenuates the
intestinal motility, slows transit, and exhibits antisecretory activity that makes it one of the
most efﬁcient drugs in the symptomatic treatment of the various types of diarrhea (12, 32,
184). Loperamide, as a much safer and well-tolerated drug, seems to be superior to
diphenoxylate (108). Diphenoxylate is often applied with atropine (276).
Pancreatic polypeptide (PP). PP is a hormone produced, almost exclusively, in
endocrine cells of the pancreas (2). PP released from the pancreas can reach the brain
through the systemic circulation or can stimulate the PP receptors in the gut. PP is also present
in nerves (298). PP acts through speciﬁc class of receptors present mainly in the various brain
regions (168, 308). The binding sites for PP within the brain are located mostly in some
cortical, subcortical, hypothalamic, and mesencephalic regions. They are also present in the
rhombencephalic areas, especially in nucleus tractus solitarius, area postrema, and dorsal
motor nucleus of the vagus (158, 307, 308). These regions remain in easy contact with the
blood. The hormone release is mostly under vagal control, thus it is possible that peripheral
cholinergic inﬂuences are also implicated in the hormone action (164, 182, 248). Other
mechanisms affecting PP release seem secondary or not important. However, a certain role of
motilin in PP action can be postulated (306). PP level in the blood ﬂuctuates in accordance
with the MMC in the fasted state and is elevated after the meal (126, 274). PP is also released
by sham feeding and by other feeding-related procedures (2, 249, 274). PP receptors may also
be present in the gut (88). The hormone increases motor activity in the stomach and small
bowel, accelerates gastric emptying, and promotes the intestinal transit (159). It is unlikely
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that these effects are not mediated by the enteric nervous system (237). The data illustrating
the effect of PP upon the MMC are inconsistent. As it was found in dog, the moderate dose
of PP blocked the MMC in the stomach and upper small intestine, whereas the lower dose
was rather ineffective (102, 279). Another study on dogs and pigs showed that the higher
doses of PP increased the frequency of the MMC (27). In rats, PP inhibited the motility and
disrupted the MMC pattern in both the duodenum and the jejunum (6, 241). The central
effect of PP mediated by vagus seems to be more important in dogs than in rats, while the
role of the sympathetic nervous system is negligible (39, 241). The effects of PP can be
modiﬁed by the concomitant alteration of motilin level. The results derived from several
reports indicate that PP can act peripherally as the motilin antagonist in the control of
gastrointestinal motility including the MMC (6, 39, 102, 126, 279). It does not exclude the
possibility of the central action of PP, although the mediatory role of the cholinergic system
in the PP control of the MMC still remains unclear.
Finally, it can be proposed that PP regulates the gastrointestinal MMC pattern, possibly
in cooperation with motilin, and the mediatory role of the cholinergic mechanisms in the
control of MMC by PP is very probable. Central, rather than peripheral cholinergic
mechanisms may be principally involved, but the meaningful mediatory role of the enteric
nervous system seems to occur as well.
Neurotensin
Neurotensin is produced in the brain, gastrointestinal nerves, and also in ileal and jejunal
mucosa (N cells), while its smaller amounts are present in the stomach and in other intestinal
regions (14, 64, 79, 138, 198, 246). Neurotensin receptors are expressed in the brain,
gastrointestinal mucosa and submucosa as well as in both the myenteric and submucous
plexus (92, 232, 250, 293). Neurotensin can be released postprandially and fat is the most
potent stimulus (280). The hormone is released mainly from the gut, since ileal resection can
abolish fat-induced neurotensin release (297). As atropine markedly inhibited neurotensin
release in man and dog, hormone release appears to be under cholinergic control
(74, 77). The hormone inhibits the gastrointestinal motility and gastric emptying, but in
vitro studies indicated that small doses of the hormone exert stimulatory effects (133, 209).
These contractions are rather not propulsive. Small doses of neurotensin, injected intraarteri-
ally into the small bowel segment, exerted inhibitory effects on canine duodenal and ileal
motility (221). Neurotensin may act directly on the smooth muscle, suggesting that the
endocrine or neuroendocrine pathways appear to represent important mechanisms underlying
the effects (216, 221). However, neurotensin inhibited contractile activity, also through
neural pathways, releasing norepinephrine that activated primarily α2-adrenoceptors that
inhibit, in turn, the acetylcholine release. In the small bowel, neurotensin converted the
fasting pattern (MMC) into the fed pattern that was observed in men, dogs, and rats (5, 252,
278). The effect was prevented by vagotomy and the administration of atropine and
hexamethonium (4). When neurotensin was inoculated intracerebroventricularly in the fasted
state, canine jejunal MMC was replaced by isolated phases of regular activity, whereas
neurotensin administered to the fed rats restored the MMC pattern (22, 25). Therefore,
considering the action on gastrointestinal motility, neurotensin can be called the gut-brain
peptide (51).
Neurotensin belongs to the regulators inhibiting the MMC mostly in the neuroendocrine
pathway(s). The involvement of the enteric nervous system in the neurotensin action on the
cessation of the MMC has not been precisely elucidated, but seems to be very likely.
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Cholecystokinin (CCK)
CCK occurs in several forms in endocrine I cells, mainly in the jejunum, where it is
synthesized and stored (144, 156). It is also released from these cells. Furthermore, CCK is
synthesized in neurons. CCK-containing neurons are the most common in brain and are also
present in the enteric neurons, mostly in the submucosal plexus (59, 84, 204). The hormone
was identiﬁed in the myenteric neurons as well, especially as CCK octapeptide (145, 246).
CCK exerts its action after binding with speciﬁc receptors present in neuronal and non-
neuronal tissues. Within the nervous system, CCK receptors were found in the brain and
vagus nerve (119, 257, 324). CCK receptors are also expressed by the gastrointestinal tissue
(298). Principally, two CCK receptors were recognized, CCK-A (CCK1) and CCK-B/gastrin
(CCK2), both present in the nervous system and the gastrointestinal tract. CCK-A receptor
exhibits high afﬁnity to CCK. It was identiﬁed in the pylorus, vagus nerve, enteric neurons,
and in the central nervous system. CCK-B receptor exhibits lower afﬁnity to CCK. It mostly
occurs in the stomach and central nervous system (61, 183). CCK can act through both
receptors. It is released from endocrine cells directly by food and food components, like some
fatty acids and few types of amino acids, or by some CCK-releasing putative luminal factors
(110, 111, 140, 157, 167, 256). Apart from various actions of CCK, some of its effects on the
gastrointestinal motility appear to be physiological. The hormone exerts stimulatory effects
on various parts of the stomach, but inhibits gastric emptying due to the relaxation of its
proximal part and the contraction of the pylorus (52, 86, 322). Moreover, CCK stimulates
small intestinal motility and shortens the intestinal transit. However, there are no data
showing that CCK evokes propulsive contractions (101, 154). In the fasting state, CCK
causes the disruption of the MMC, at least in the dog. Following CCK administration and
MMC inhibition, the character of alternative motility, which replaces the MMC, does not
resemble the fed pattern and plasma motilin cycling is preserved (179, 315). In rats,
endogenous CCK also disrupted the MMC (208). The mechanism of CCK action on the
gastrointestinal motility is complex. CCK-A receptor occurs in the vagal afferents and CCK
can stimulate it in the stomach, thus affecting both the motility and emptying (202, 247).
Modulation of gastric motility by CCK in the endocrine pathway is possible, but it has also
been demonstrated that CCK activates vago-vagal reﬂexes in the gut (61). The neural
mechanisms of CCK action on small intestinal motility appear to predominate. CCK induces
contractions of the circular muscle layer and inhibits contractions of the longitudinal muscle
layer (258). The effects are antagonized by atropine, hexamethonium, and depolarizing doses
of nicotine, which suggest that CCK activates cholinergic receptors on postganglionic
cholinergic neurons in the gut. In the isolated gastroduodenal preparations, CCK induced
motor activity in the neural pathway and also induced contractions, acting directly on the
muscle (238). In the isolated gastric smooth muscle cells, CCK induced contractions as well
(44). Responses to nutrients, mediated by CCK, are also transmitted through the neural
pathway (66). The delay or disruption of the MMC by CCK can be regulated centrally (21).
The endogenous CCK can act on vagal-afferent CCK-B receptors to stimulate central CCK-A
receptor to disrupt the MMC (208). Furthermore, low doses of CCK applied in the
autotransplanted proximal gastric pouches, effectively inhibited normal interdigestive cycles
(234). The effect was local, although it is uncertain whether it occurred in the neural pathway.
Thus, CCK can centrally control the gastrointestinal motility, including the MMC
pattern, but the enteric neural mechanisms are also engaged. The involvement of endocrine
pathways, mediating the effects of CCK upon the gastrointestinal motility, is possible,
although their role in the control of the MMC is doubtful.
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Gastrin
The natural gastrin mostly occurs as a heptadecapeptide, G17 (sulfated and non-sulfated)
and also as G34, while little is known about the physiological role of other gastrin forms
like G14 or G71 (61). Pentagastrin is the common exogenous form of gastrin exhibiting full
gastrin activity. Gastrin is synthesized and released from the G cells distributed mostly in
the pyloric antrum and also in the duodenum. Small amounts of gastrin are present in the
vagus nerve and pituitary (203, 288). The presence of gastrin in the brain is uncertain (61).
Multiple gastrin actions are mediated by speciﬁc receptors, i.e., almost exclusively by the
CCK-B/gastrin receptor, since the afﬁnity of the gastrin to CCK-A receptor is approxi-
mately 1,000 times smaller than that of CCK (298). Gastrin is released by food and by
elevation of gastric pH, while strong acidiﬁcation inhibits gastrin release. Some nutrients,
such as peptides and amino acids, enhance gastrin release (299). Calcium, neural reﬂexes,
and circulating catecholamines represent other releasing factors. The role of the nervous
system, i.e., cholinergic enteric neurons and vagus nerve in gastrin release, is complex and
important. Among other hormones, the bombesin-like peptide, namely the gastrin-releasing
peptide (GRP), also called the mammalian bombesin, can increase gastrin release from its
endocrine stores (244). GRP release is mediated by the neural pathway. Within the
gastrointestinal tract, gastrin receptors are expressed by both the gastric parietal cells
and the enterochromafﬁn cells, and some by the smooth muscle cells. They are also
present in the neurons of the central and peripheral nervous system (61). Gastrin effect
upon the gastrointestinal motility is rather stimulatory (298). It increases gastric antral
contractions in vitro and in vivo, although in the proximal stomach, its effect is inhibitory
that could be associated with concomitant somatostatin release (135, 177, 245, 298, 311).
Gastrin slows gastric emptying despite the initiation of propulsive types of contractions in
the distal stomach. Decreasing the intragastric pressure can be one of the reasons of this
response (46, 135). Gastrin also stimulates the intestinal motility (253, 295). In many
cases, gastrin appears to exert its effect upon the gastrointestinal motility acting directly
on the smooth muscle (298). It was found that pentagastrin excited antral longitudinal
muscle by the release of acetylcholine and directly stimulated the circular muscle layer
(261). In the guinea pig ileum, it acted through the neural mechanisms since the motor
response was abolished by tetrodotoxin and attenuated by atropine (295). Gastrin also
disrupts the MMC pattern that was demonstrated clearly in the dog, although it does not
seem to reproduce the fed pattern (68, 163, 304). The disruption of the interdigestive
pattern was also observed after bilateral vagotomy (163). However, when pentagastrin
infusion was stopped in vagotomized dogs, the MMC was initiated again in the stomach
and the duodenum. Therefore, it can be assumed that gastrin can inhibit the initiation of
the MMC from the stomach and the duodenum, acting directly on the smooth muscle.
Possible involvement of central mechanisms in the changes in the MMC, evoked by
gastrin, cannot however be excluded. Since both feeding and sham feeding strongly
evoke gastrin release, the hormone contributes to the inhibition of MMC by food. Gastrin
release is mediated by the vagus nerve and this response was found to be resistant to
atropine administration (62, 275).
In summary, gastrin participates in the postprandial MMC inhibition, though its precise
mechanism of action is still uncertain. Although gastrin receptors are sparse in the
gastrointestinal nerves and only few gastrin cells are in the gut, the role of endocrine
mechanism in the inhibition of the MMC by gastrin is possible, while the data indicating the
involvement of neural mechanisms are also available.
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Conclusions
Several neuropeptides and other regulators, members of the NANC system, contribute to the
control of the MMC within the enteric nervous system (60, 61, 72). The best recognized
regulators were discussed earlier and characterized in Table I. Apart from the hormonal
factors described earlier there are some others which can also participate in the control of the
MMC (106, 213), but little is known concerning their distribution, receptor localization, and
mechanism of action. Considering the presented major hormonal regulators of the MMC
pattern, it can be concluded that the neural mechanisms predominate in their action on the
gastrointestinal motility and all the factors may inﬂuence the MMC through the central and/or
peripheral neural controlling pathways. Therefore, they can regulate the MMC mostly as
neuromodulators. Their inﬂuence through the endocrine and paracrine pathways may concern
rather the initiation and modiﬁcation of the individual contractions, including the contractions
occurring within the MMC cycle. Indeed, these factors induce or disrupt the phase III of the
cycle, but in this respect their direct action on the smooth muscle appears less important. They
do not seem to be responsible for the migration of phase III and for the whole cycle along the
bowel. It is unwarrantable to assert that the MMC can migrate without the contribution of the
enteric nervous system. Furthermore, the initiation and migration of the MMC may require
the engagement of relaxation oscillators, apparently linked to the enteric nervous system,
since some enteric neurons may contain an internal clock (224). The distribution of chemical
regulators in the gastrointestinal tract and distribution of their receptors are variable and there
are several important species differences. The variabilities hindered the understanding of the
regulators’ contribution in the control of the MMC cycles, especially of those conﬁned to the
endocrine and paracrine pathways. Luminal chemical factors appear to be directly responsi-
ble for the initiation of the MMC. The hormone-dependent induction of phase III may occur
in one locus, although other mechanisms might be responsible for the migration of phase III
or for the organization and migration of the MMC along the gut. Some chemical factors
responsible for the cessation of the MMC also seem to act in cooperation with the nervous
system. These substances may not be widely distributed throughout the gastrointestinal tract
and they are thus able to achieve sufﬁcient concentration only in a relatively short bowel
segment. Their physiological role in the control of the MMC has not been well recognized,
but they can ﬁnally act rather as neuromodulators or neurotransmitters than as hormones.
Figure 2 illustrates the possible pathways engaged in the control of the MMC by
chemical factors.
The Role of Intrinsic Innervation in the Control of the MMC
MMC initiation
Itoh et al. (124) and Ormsbee et al. (187) prepared dogs with Thiry-Vella intestinal loops and
found that MMC cycling within the loop is not related to its cycling in the rest of the bowel.
Both the vagal cooling at the thoracic level and vagotomy did not block the MMC arrival in
the gut (90, 272). The duodenojejunectomy inhibited the MMC in the stomach (270). Finally,
close intraarterial injections of atropine and hexamethonium into the small intestinal segment
exerted the inhibitory effect on the MMC within and beyond this segment (227). All the
results indicate the meaningful role of the enteric innervation in the initiation and mainte-
nance of the MMC in the stomach and small bowel. When the MMC is triggered centrally, the
enteric nerves have to mediate this signal. The MMC, as a rhythmic phenomenon, can be
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triggered continuously by the central metronome (113, 171, 326). Thus, both central and
peripheral initiation of the MMC appears to be equally important.
MMC migration (maintenance)
The arrival and migration of the MMC along the gastrointestinal tract may be dependent on
the activity of the series of relaxation oscillators that might be located rather in the enteric
nervous system along with the clock genes (223, 224, 313). Thus, melatonin might be
suspected to continue its central role in the periphery as well (166, 281). The peripheral
mechanism can be directly responsible for the migration of the MMC along the bowel. It well
explains the occurrence of ectopic fronts and of rebound-type responses observed following
the atropine or hexamethonium administration. When the response exhibited the migratory
character, it resembled phase III of the MMC. When it was stationary and prolonged, it was
clearly different from phase III (30, 142, 210, 211, 214, 219, 283, 289). However, the
stationary phase III of the MMC can also occur, but it does not seem to be the normal motility
pattern. Furthermore, atropine and hexamethonium are able to inhibit phasic contractions,
thus blocking the contractile mechanisms which also affect the MMC (230). The results
conﬁrmed the importance of the enteric nervous system in the control of the MMC. When the
intestinal transection, followed by reanastomosis, was performed, both intrinsic neural and,
Fig. 2. Scheme presenting possible neurocrine and neuroendocrine pathways involved in the control of the migrating
motor complex. I. Extrinsic neurocrine pathway. Neuromodulator is released from the enteric ganglia in response to
smooth muscle contraction or relaxation, or to other signals. Then, the neuromodulator affects the brain centers
evoking the response sent through the efferent ﬁbers (preferentially the vagus nerve). II. Intrinsic neurocrine pathway.
The neuromodulator is released from the enteric ganglia spontaneously or in response to the signals from the smooth
muscle. Then, the neuromodulator elicits the smooth muscle contractile response. III. Extrinsic neuroendocrine
pathway. The hormonal neuromodulator is released to the blood from the endocrine cells in response to the local
(e.g., luminal) stimuli or signals from the enteric ganglia. Then, the neuromodulator evokes central response returned
(preferentially by the vagus nerve) either to the enteric ganglia and then to the smooth muscle or directly from the
brain to the smooth muscle eliciting ﬁnal contractile response. IV. Intrinsic neuroendocrine pathway. The hormonal
neuromodulator is released to the blood from endocrine cells in response both to the local (e.g., luminal) stimuli and
signals from the enteric ganglia. Then, the neuromodulator evokes the contractile effect of the smooth muscle. The
neuromodulator can also originate from the lumen and act on the enteric nerves or directly on the smooth muscle
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perhaps also, vagal connections were damaged (226). The small bowel was divided into
the smaller segments and each of them exhibited the presence of independent MMC. About
2–3 months following surgery, the coordination between the MMCs present in the segments
gradually returned. Thus, the enteric nervous system was primarily responsible for restoring
the coordination and for MMC maintenance.
MMC cessation
The experiments demonstrating the existence of the cephalic phase of the MMC control
provide an evidence for a central inhibition of the MMC (55, 199). When several hormones
like gastrin, CCK, PP (see above), and secretin or insulin are released by feeding, they
disrupt the MMC in the same way as food does, but their precise mechanism of action is
unclear (223). It is difﬁcult to discriminate between the endocrine and neurocrine actions of
these hormones. However, both mechanisms are possibly involved, although the endocrine
pathway of MMC inhibition is less probable since its receptors are not always present on
the smooth muscles or their density may not be sufﬁcient. These receptors are often
stimulatory with respect to the gastrointestinal motility. In addition, the smooth muscles
appear to be rather an executory than an initiatory organ regarding the arrival of the MMC
pattern. Thus, the hormones can possibly stimulate or inhibit in this way only the individual
contractions, not the whole MMC pattern for which more composed mechanism might be
desired. The neurocrine pathway may require smaller amounts of the hormone and the
regulatory substances can act locally, directly on the intestinal oscillator (109). It is possible
that food or nutrients can directly stimulate the release of the hormones (15). The mucosal
receptors are sensitive to the nutrients and mechanical stimuli. They transmit signals to the
enteric nervous system directly or through the mediatory substances released from the
mucosa. Finally, various mediators operate within the enteric neurons in response to
mucosal signals (1, 24, 47, 73, 80, 160, 181, 201). Therefore, it is possible that not only
chemical or mechanical factors, but also the intrinsic nerves participate in the cessation of
the MMC.
The Overall Control of the MMC
The nervous system appears to predominate in the control of the MMC (57). The MMC
seems to be initiated centrally all the time, but the local mechanisms decide about its
occurrence in the gastrointestinal tract. When the central oscillator is blocked, the MMC cycle
can be initiated by the gastric or upper enteric oscillator. In the case when the upper enteric
oscillator cannot be active, the lower oscillator initiates the MMC, while the subsequent
oscillators are responsible for the migration of the MMC down, along the bowel. It is possible
that once a given oscillator is stimulated, it stimulates the next one and so forth (314). The
mechanism can also be engaged when the ectopic front occurs. When the MMC returns
sometimes after feeding, its phase III is usually ectopic (71). In this situation, the upper
oscillators remain inactive and the ﬁrst activated oscillator represents one of the lower
oscillators. It means that the lower oscillators are more reactive than the upper oscillator. The
event can be explained by the different sensitivities of the intestinal segments to the factors
initiating and disrupting the MMC. It is possible that the role of the central oscillator is to
facilitate the MMC occurrence in the gastrointestinal tract, whereas the peripheral oscillator is
responsible for its ﬁnal initiation and migration. In all or almost all the MMC-controlling
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mechanisms the enteric nervous system is involved. Accordingly, the chemical factors
regulating the MMC, can act primarily in the neuroendocrine pathway. It could be really
difﬁcult to identify a pure hormonal mechanism controlling the MMC. Even the hormones
released from the endocrine cells and acting in the paracrine route may exert their effect rather
through neural mechanisms. There are some marked regional differences in the regulatory
mechanisms. For example, motilin induces the MMC from the stomach, but somatostatin
exerts a stronger effect on the MMC in the small bowel. The role of other hormones may also
be different in various parts of the digestive tract. While neurotensin converts the MMC to the
fed pattern, CCK and gastrin contribute only to the MMC inhibition. It seems likely that the
local mechanisms determine mainly the character of the variabilities within the MMC and
some species differences. It is ﬁnally asserted that the peripheral neural mechanisms, linked
to the enteric nervous system, are crucial in the control of the MMC. However, central MMC-
controlling mechanisms cannot be disregarded, though the complicity of peripheral mechan-
isms controlling the MMC is required for their normal functioning. Figure 3 presents possible
routes and mechanisms active in the overall control of the MMC.
Since the mechanisms controlling the MMC are still incompletely understood, the future
progress will mostly depend upon the application of more composed and precise techniques.
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